rejuveron life sciences ag
- Rejuveron raises $75 million in dual tranche Series B and convertible loan financing to support healthy aging and accelerate presence in the Middle East
- Second Rejuveron company transitions into clinical stage as first patient is dosed in trial of Endogena Therapeutics’ novel regenerative treatment for blindness caused by retinitis pigmentosa
- Global Meetup in Zürich
- “Aging intersects with absolutely every other aspect of human experience”
- “My survival instinct sparked me to get into aging research”
No comments to show.